Table 1:
Some of the main SARS-CoV-2 vaccines under development (38)
| Compound | Sponsor | Modality | Type | Phase (COVID-19) |
|---|---|---|---|---|
| Anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin | CSL; Takeda; Biotest; BPL; LFB; Octapharma | Biologic | Therapy | Preclin |
| Anti-SARS-CoV-2 hyperimmune globulin | Grifols | Antibody | Therapy | Preclin |
| CORVax12 | OncoSec | DNA vaccine | Vaccine | IND |
| CoroFlu | FluGen / Bharat Biotech | Viral vaccine | Vaccine | Preclin |
| CV-15 (iCP-NI) | Cellivery Therapeutics | Peptide | Therapy | Preclin |
| EIDD-2801 | Emory University; Ridgeback Biotherapeutics | Small molecule | Therapy | Preclin |
| ExpreS2-CoV | ExpreS2ion Biotech Holding; AdaptVac; University of Tübingen; Leiden University Medical Center; University of Copenhagen; Wageningen University | Protein-based | Vaccine | Preclin |
| Ii-Key-SARS-2 | Generex Biotechnology; EpiVax | Protein-based | Vaccine | Preclin |
| ISR50 | ISR | Small molecule | Therapy | Preclin |
| LUNAR-COV19 | Arcturus Therapeutics; Duke-NUS Medical School | RNA vaccine | Vaccine | Preclin |
| NCP112 | NovaCell Technology | Peptide | Therapy | Preclin |
| Neumifil | Pneumagen | Protein | Therapy | Preclin |
| PRTX007 | Primmune Therapeutics | Small molecule | Therapy | Preclin |
| Unnamed | Baylor College of Medicine; University of Texas Medical Branch; New York Blood Center; Fudan University | Protein-based | Vaccine | Preclin |
| WP1122 | Moleculin Biotech | Small molecule | Therapy | Preclin |
| Kainos small molecule antivirals | Kainos Medicine | Small molecule | Therapy | Preclin |
| Ad26 SARS-CoV-2 | Johnson & Johnson; Beth Israel Deaconess Medical Center; BARDA | Viral vector | Vaccine | Preclin |
| AdCOVID | Altimmune; University of Alabama | Viral vector | Vaccine | Preclin |
| BNT162 | BioNTech; Pfizer; Fosun Pharma | RNA vaccine | Vaccine | Preclin |
| COVID-19 S-Trimer Vaccine | Sichuan Clover Biopharmaceuticals; Dynavax | Protein-based | Vaccine | Preclin |
| COVID-HIG | Emergent BioSolutions; BARDA | Antibody | Therapy | Preclin |
| COVID-EIG | Emergent BioSolutions | Antibody | Therapy | Preclin |
| Coronavirus VLP | Mitsubishi Tanabe (Medicago) | Vaccine | Vaccine | Preclin |
| DPX-COVID-19 | IMV | Protein-based | Vaccine | Preclin |
| IBIO-200 | iBio; Texas A&M University | Protein-based | Vaccine | Preclin |
| ISR50 | ISR | Small molecule | Therapy | Preclin |
| NI007 | Neurimmune; Ethris | Antibody; RNA | Therapy | Preclin |
| rCIG | GigaGen | Antibody | Therapy | Preclin |
| SAB-185 | SAB Biotherapeutics; BARDA | Antibody | Therapy | Preclin |
| STI-4398 | Sorrento Therapeutics | Fusion protein | Therapy | Preclin |
| STI-6991 | Sorrento Therapeutics | Cellular vaccine | Vaccine | Preclin |
| TAK-888 | Takeda Pharmaceutical | Antibody | Therapy | Preclin |
| TNX-1800 | Tonix Pharmaceuticals; Southern Research Institute | Engineered live attenuated virus | Vaccine | Preclin |
| VIR-7831 | Vir Biotechnology; GlaxoSmithKline | Antibody | Therapy | Preclin |
| VIR-7832 | Vir Biotechnology; GlaxoSmithKline | Antibody | Therapy | Preclin |